42 publications

– Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008 Nov 13;359(20):2121-34.

– Barbot AC, Mussault P, Ingrand P, Tourani JM. Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. J Clin Oncol 2008; 26(15):2538-2543.

– Cortes J, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Rudoltz M, Yu R, Collins L, Krahnke T, Radich JP, Hughes TP. A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study. Blood 2008; 112(11):335.

– Gambacorti-Passerini C, Kim DW, Mahon FX, Saglio G, Pane F, Guilhot F, Deininger MWN, Nagler A, Rambaldi A, Morra E, Antolini L, Kweon IY, Reiffers J, Tornaghi L, Valsecchi MG. Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients. Blood 2008; 112(11):1099.

Guilhot F, Hughes TP, Cortes J, Wang Y, Hayes M, Gichangi A, Druker BJ, Baccarani M. (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study TOPS). Blood 2008; 112(11):447.

Guilhot F, Mahon FX, Guilhot J, Rigual-Huguet F, Maloisel F, Rousselot P, Gardembas M, Corm S, Guerci A, Vekhoff A, Etienne G, Legros L, Kiladjian J, Jourdan E, Schoenwald M, Berger M, Eclache V, Roche-Lestienne C, Nicolini FE, Preudhomme C. Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC). Blood 2008; 112(11):183.

– Hughes TP, Hochhaus A, Branford S, Muller MC, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Waltzman RJ, Mone M, Wehrle E, Radich JP, Goldman JM. Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). Blood 2008; 112(11):334.

– Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111(8):4022-4028.

– Mahon FX, Huguet F, Guilhot F, Legros L, Nicolini FE, Charbonnier A, Guerci A, Rea D, Varet BR, Gardembas M, Guilhot J, Etienne G, Milpied NJ, Aton E, Reiffers J, Rousselot P. Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre “ Stop Imatinib” (STIM) Study. Blood 2008; 112(11):187.

– O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Rudoltz M, Filian J, Gathmann I, Druker BJ, Larson RA. International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM). Blood 2008; 112(11):186.

Hadjadj S, Fumeron F, Roussel R, Saulnier PJ, Gallois Y, Ankotche A, Travert F, Khalil CA, Miot A, Alhenc-Gelas F, Lievre M, Marre M. Prognostic Value of the Insertion/Deletion polymorphism of Angiotensin I Converting Enzyme gene in type 2 diabetic subjects: results from the DIABHYCAR, DIAB2NEPHROGENE & SURDIAGENE studies. Diabetes Care 2008 31(9):1847-52.

– Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M.Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008 Dec;22(12):2176-83.

– Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O’Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, List A. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 2008 ;22(9):1707-11.

– Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Muller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22(6):1200-1206.

– Shimoni A, Leiba M, Schleuning M, Martineau G, Renaud M, Koren-Michowitz M, Ribakovski E, le Coutre P, Arnold R, Guilhot F, Nagler A. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia 2008 ;23(1):190-4.

– Welter ML, Mallet L, Houeto JL, Karachi C, Czernecki V, Cornu P, Navarro S,Pidoux B, Dormont D, Bardinet E, Yelnik J, Damier P, Agid Y. Internal pallidal and thalamic stimulation in patients with Tourette syndrome. Arch Neurol. 2008;65(7):952-7.

– Karayan-Tapon L, Wager M, Guilhot J, Levillain P, Marquant C, Clarhaut J, Potiron V, Roche J. Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker? Br J Cancer 2008; 99(7):1153-1160.

– Wager M, Menei P, Guilhot J, Levillain P, Michalak S, Bataille B, Blanc JL, Lapierre F, Rigoard P, Milin S, Duthe F, Bonneau D, Larsen CJ, Karayan-Tapon L. Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer 2008; 98(11):1830-1838.

– Frat JP, Gissot V, Ragot S, Desachy A, Runge I, Lebert C, Robert R. Impact of obesity in mechanically ventilated patients: a prospective study. Intensive Care Med 2008; 34(11):1991-8..

– Khalifa R, Dahyot-Fizelier C, Laksiri L, Ragot S, Petitpas F, Nanadoumgar H, Debaene B, Mimoz O. Indwelling time and risk of colonization of peripheral arterial catheters in critically ill patients. Intensive Care Med 2008. ;34(10):1820-6.

– Lanquetot H, Leprince T, Ragot S, Boinot C, Jayle C, Robert R, Macchi L. Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass. Intensive Care Med 2008; 34(11):2068-2075.

– Mok E, Multon C, Piguel L, Barroso E, Goua V, Christin P, Perez MJ, Hankard R. Decreased full breastfeeding, altered practices, perceptions, and infant weight change of prepregnant obese women: a need for extra support. Pediatrics 2008; 121(5):e1319-e1324.

– Cauchi S, Meyre D, Durand E, Proenca C, Marre M, Hadjadj S, Choquet H, De Graeve F, Gaget S, Allegaert F, Delplanque J, Permutt MA, Wasson J, Blech I, Charpentier G, Balkau B, Vergnaud AC, Czernichow S, Patsch W, Chikri M, Glaser B, Sladek R, Froguel P. Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS ONE 2008; 3(5):e2031.

– Beauchant M, Ingrand P, Favriel JM, Dupuychaffray JP, Capony P, Moindrot H, Barthet M, Escourrou J, Plane C, Barrioz T, Lacoste L, Ingrand I.Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial. Endoscopy. 2008;40(8):631-6.

– Rotge JY, Clair AH, Jaafari N, Hantouche EG, Pelissolo A, Goillandeau M, Pochon JB, Guehl D, Bioulac B, Burbaud P, Tignol J, Mallet L, Aouizerate B. A challenging task for assessment of checking behaviors in obsessive-compulsive disorder. Acta Psychiatr Scand. 2008 Jun;117(6):465-73.

– Capa RL, Audiffren M, Ragot S. The effects of achievement motivation, task difficulty, and goal difficulty on physiological, behavioral, and subjective effort. Psychophysiology 2008; 45(5):859-868.

– Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol 2008; 35(1 Suppl 1):S1-17.

– Christiaens L, Ardilouze P, Ragot S, Mergy J, Allal J. Prospective evaluation of the anatomy of the coronary venous system using multidetector row computed tomography. Int J Cardiol 2008; 126(2):204-208.

– Christiaens L, Lequeux B, Ardilouze P, Ragot S, Mergy J, Herpin D, Bonnet B, Allal J. A new method for measurement of left atrial volumes using 64-slice spiral computed tomography: Comparison with two-dimensional echocardiographic techniques. Int J Cardiol 2008;131(2):217-24.

– Christiaens L, Varroud-Vial N, Ardilouze P, Ragot S, Mergy J, Bonnet B, Herpin D, Allal J. Real three-dimensional assessment of left atrial and left atrial appendage volumes by 64-slice spiral computed tomography in individuals with or without cardiovascular disease. Int J Cardiol 2008;140(2):189-96.

– Mok E, Constantin B, Favreau F, Neveux N, Magaud C, Delwail A, Hankard R. l-Glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice. Pediatr Res 2008; 63(3):268-273.

– Robert R, Deraignac A, Le Moal G, Ragot S, Grollier G. Prognostic factors and impact of antibiotherapy in 117 cases of anaerobic bacteraemia. Eur J Clin Microbiol Infect Dis 2008. ;27(8):671-8.

– Capa RL, Audiffren M, Ragot S. The interactive effect of achievement motivation and task difficulty on mental effort. Int J Psychophysiol 2008; 70(2):144-150.

– Defossez G, Verneau A, Ingrand I, Silvain C, Ingrand P, Beauchant M; Poitou-Charentes Hepatitis C Network.Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol. 2008;20(5):367-72.

Hadjadj S, Saulnier PJ, Torremocha F, Labbe L, Marechaud R. To what extent should we lower HbA1c in diabetic subjects? Diabetes Metab 2008; 34 Suppl 1:S37-S40.

Guilhot F, Roy L, Saulnier PJ, Guilhot J, Barra A, Gombert JM, Turhan A. Immunotherapeutic approaches in chronic myelogenous leukemia. Leuk Lymphoma 2008; 49(4):629-634.

Saulnier PJ, Dalbies F, Berthou C, Guilhot F, Bourmeyster N, Chomel JC, Thuran A. Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy. Leuk Lymphoma 2008; 49(4):815-816.

– Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Blood Coagul Fibrinolysis. 2008 Apr;19(3):235-9.

– Bensimhon L, Metaye T, Guilhot J, Perdrisot R. Influence of temperature on the radiochemical purity of 99mTc-colloidal rhenium sulfide for use in sentinel node localization. Nucl Med Commun 2008; 29(11):1015-1020.

– Azulay N, Forgerit M, Alava EG, Deplas A, Vialle R, Ragot S, Tasu JP. A novel radiofrequency thermocoagulation method for treatment of lower back pain: thermal conduction after instillation of saline solution into the nucleus pulposus–preliminary results. Acta Radiol 2008; 49(8):934-939.

Jaafari N, Brzozowski M, Rotge JY, Sharov I, Bates H, Paillot C, Debaene B, Camus V, El Hage W, Quentin S, Millet B, Senon JL. ECT as a ‘therapeutic test’ to differentiate pharmaco-resistant depression from dementia in the elderly: a pilot study. Primary Care and Community Psychiatry 2008; 13:155-161.

Ingrand I, Dujoncquoy S, Migeot V, Ghadi V, Beauchant M, Ingrand P.Interactions among physicians, patients, and first-degree relatives in the familial screening of colorectal cancer in France. Patient Prefer Adherence. 2008;2:47-55.